Neuroendocrine Tumour of the Lung Terminated Phase 3 Trials for Lanreotide (DB06791)

Also known as: Pulmonary Neuroendocrine Tumor / Neuroendocrine Neoplasm of Lung / Neuroendocrine Tumor of the Lung / Pulmonary Neuroendocrine Tumors / Neuroendocrine Tumors in Lung / Neuroendocrine neoplasm of lung (disorder)

IndicationStatusPhase
DBCOND0133412 (Neuroendocrine Tumour of the Lung)Terminated3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02683941Efficacy and Safety of Lanreotide Autogel/ Depot 120 mg vs. Placebo in Subjects With Lung Neuroendocrine TumoursTreatment